A.3.a. How many were initiated (or continued) on first-line osteoporosis medication (alendronate, risedronate, zoledronic acid, denosumab or teriparatide) within 26 weeks of their hip fracture?
A.3.b. How many were not initiated a first-line osteoporosis medication within 26 weeks of their hip fractures?
A.3.c. How many are you not sure if the patient was initiated or not on osteoporosis medication within 26 weeks (e.g. patient lost to follow-up)?
a. Hip (proximal femur) fractures
b. Wrist (distal radius) fractures
c. Shoulder (proximal humerus) fractures
e. Spine/vertebral fractures
d. Fracture risk could not be determined within 26 weeks
B.4.a. How many were initiated (or continued) on first-line osteoporosis medication (alendronate, risedronate, zoledronic acid, denosumab or teriparatide) within 26 weeks of their fracture?
B.4.b. How many were not initiated a first-line osteoporosis medication within 26 weeks of their fractures?
B.4.c. How many are you not sure if the patient was initiated or not on osteoporosis medication within 26 weeks (e.g. patient lost to follow-up)?
a. Hip (proximal femur) fractures (within 12 wks)
b. Wrist (distal radius) fractures (within 6 wks)
c. Shoulder (proximal humerus) fractures (within 6 wks)
d. Pelvic fractures (within 6wks)
e. Spine/vertebral fractures
d. Fracture risk could not be determined within 26 weeks
a. How many were initiated (or continued) on first-line osteoporosis medication (alendronate, risedronate, zoledronic acid, denosumab or teriparatide) within 26 weeks of their fracture?
b. How many were not initiated a first-line osteoporosis medication within 26 weeks of their fractures?
c. How many are you not sure if the patient was initiated or not on osteoporosis medication within 26 weeks (e.g. patient lost to follow-up)?
a. Hip (proximal femur) fractures (within 12 wks)
b. Wrist (distal radius) fractures (within 6 wks)
c. Shoulder (proximal humerus) fractures (within 6 wks)
d. Pelvic fractures (within 6 wks)
e. Spine/vertebral fractures
d. Fracture risk could not be determined within 26 weeks
a. How many were initiated (or continued) on first-line osteoporosis medication (alendronate, risedronate, zoledronic acid, denosumab or teriparatide) within 26 weeks of their fracture?
b. How many were not initiated a first-line osteoporosis medication within 26 weeks of their fractures?
c. How many are you not sure if the patient was initiated or not on osteoporosis medication within 26 weeks (e.g. patient lost to follow-up)?